News & Events

Researchers have discovered that free radicals generated at a specific site in non-neuronal brain cells called astrocytes, may promote dementia, according to a Weill Cornell Medicine study. Their findings, published Nov. 4 in Nature Metabolism, demonstrated that blocking this site lowered brain inflammation and protected neurons, suggesting a novel therapeutic approach for neurodegenerative disorders, including frontotemporal...

Investigators at Weill Cornell Medicine have developed a versatile and non-toxic technology for controlling the activity of any gene in a cell. Such “gene-switch” tools allow scientists to “turn on” or “turn off” a target gene to study how it works, model diseases and design new therapies. The tool potentially could be adopted throughout biomedical research, including in the development of gene therapies.

A Weill Cornell Medicine investigator and other members of a technical advisory group to the World Health Organization and United Nations Children’s Fund have outlined measures that nations can take to ensure that children’s health is accounted for within climate change goals. The authors discuss concrete and achievable indicators in...

As Medicaid funding cuts enacted through the One Big Beautiful Bill Act are expected to reduce health coverage among adults, researchers and clinicians from Weill Cornell Medicine, NewYork-Presbyterian and Ariadne Labs argue in a New England Journal of Medicine perspective, published Nov. 1, that children are at increasing risk of unintended downstream effects.

A team led by Weill Cornell Medicine and University of Miami’s Miller School of Medicine investigators has been awarded a five-year, $4 million grant from the National Institute on Drug Abuse (NIDA) for health economics research. The team will study the economics of substance use disorder treatments and overdose prevention strategies for individuals who are incarcerated or otherwise involved in the United States’ criminal legal system.

Interventions for people with substance use...

A group of first-year Weill Cornell medical students walk into a dimly lit room and see a person lying on the floor with alcohol and pill bottles nearby.

After calling 911, they assess the situation and decide to administer naloxone, a medication to reverse an opioid overdose. The woman starts to wake up.

"What happened?" she asked, her voice filled with confusion and fear. A student kneeling next to her introduces himself and assures her help is on the way.

The scene looks...

A three-year, $4.5 million grant from BD²: Breakthrough Discoveries for thriving with Bipolar Disorder to Weill Cornell Medicine investigators, in collaboration with Stanford Medicine, will support a three-pronged research project to map the brain circuits that contribute to mood shifts in bipolar disorder and help develop personalized therapies for the condition.

New York, NY (October 23, 2025) Albert Einstein College of Medicine has received a five-year, $10.8 million grant from the National Institutes of Health (NIH) to create the New York Regional Diabetes Research Center (NYR-DRC), a newly expanded multi-institutional center co-led with the Icahn School of Medicine at Mount Sinai and Weill Cornell Medicine. The center will focus on discovering scientific...

New York (Oct. 21, 2025)—Dr. J Mocco, an esteemed physician-scientist who specializes in cerebrovascular and endovascular neurosurgery, has been appointed chair of the Department of Neurological Surgery at Weill Cornell Medicine and neurosurgeon-in-chief at NewYork-Presbyterian/Weill Cornell Medical Center, effective Dec. 1.

Dr. Mocco will lead a large team of neurosurgeons and...

Researchers at Weill Cornell Medicine have received a five-year grant from the National Institute of Diabetes and Digestive and Kidney Diseases to support TRACE, a Tool for Reproducible, Accurate Contour Estimation. Driven by artificial intelligence, TRACE measures organ volumes from images of patients with autosomal dominant polycystic kidney disease (PKD). The standardized data and expert imaging analyses will be available to scientists nationally, which will help accelerate discoveries...

(New York, Oct. 16, 2025)—Dr. Lauren Henderson, a physician-scientist whose research focuses on children with difficult-to-treat juvenile idiopathic arthritis and other autoimmune disorders, has been awarded the 10th annual Gale and Ira Drukier Prize in Children’s Health Research, Weill Cornell Medicine announced today.           

The Drukier Prize honors an early-career pediatrician whose research promises to make important...

A state-of-the-art health screening van launched this month is bringing advanced imaging technology and health education directly to New Yorkers who are at the greatest risk of developing lung cancer. The initiative — a collaboration between Weill Cornell Imaging at NewYork-Presbyterian, the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian/Columbia University Irving Medical Center, and the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine — is designed to make...

Scientists have discovered a method to induce human endothelial cells from a small biopsy sample to multiply in the laboratory, producing more than enough cells to replace damaged blood vessels or nourish organs for transplantation, according to a preclinical study by Weill Cornell Medicine investigators. Endothelial cells form the inner lining of blood vessels and regulate blood flow, inflammation and healing. Traditional approaches for growing these cells in the lab have yielded only...

Among preterm newborns, greater exposure to the mother’s voice after birth appeared to speed up the maturation of a key language-related brain circuit, in a small clinical trial conducted by investigators at Weill Cornell Medicine, Burke Neurological Institute and Stanford Medicine. The finding provides direct experimental support for the idea that a mother’s voice promotes her child’s early language-...

A new tool developed by Weill Cornell Medicine and the University of Adelaide investigators has enhanced the ability to track multiple gene mutations while simultaneously recording gene activity in individual cancer cells. The technology, which can now use diverse types of pathology samples and quickly process large numbers of cells, has enabled the investigators to glean new insights into how cancers evolve toward greater aggressiveness and therapy resistance.

Dr. Judy Tung, a leading expert in internal medicine and primary care, has been named chief of the Division of General Internal Medicine in the Weill Department of Medicine at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center, effective Aug. 1.

The division unifies hospital medicine and outpatient...

Advances in prostate cancer early detection and treatment have improved outcomes in men diagnosed with the disease. Yet doctors and scientists...

Triple negative breast cancer (TNBC) is one of the most aggressive and hardest to treat breast cancers, but a new study led by Weill Cornell Medicine suggests a way to stop it from spreading. Researchers have discovered that an enzyme called EZH2 drives TNBC cells to divide abnormally, which enables them to relocate to distant organs. The preclinical study also found drugs that block EZH2 could restore order to dividing cells and thwart the spread of TNBC cells.

“Metastasis is the main...

A new tool greatly improves scientists’ ability to identify and study proteins that regulate gene activity in cells, according to research led by Weill Cornell Medicine investigators. The technology should enable and enhance investigations in both fundamental biology and disease research.

The activity of a gene is often regulated—switched on, sped up, slowed down, switched off—by one or more proteins that bind to DNA to exert their effect. However, identifying these DNA-binding...

Investigators at Weill Cornell Medicine and Cornell’s Ithaca campus have received a $5.1 million, three-year grant from the National Institutes of Health’s Autism Data Science Initiative (ADSI) to launch the Autism Replication, Validation, and Reproducibility (AR²) Center. The center aims to improve the reliability of autism research and foster public trust in the field.